Analysis of platelet apheresis transfusion trends in Suzhou from 2017-2022
Objective To investigate the clinical characteristics of patients who underwent multiple platelet transfusions (≥2 times) in Suzhou over the past 5 years(2017-2022),as to provide new insights for patients requiring long-term and substantial platelet transfusions. Methods A retrospective analysis was conducted on the type of diseases,volume and fre-quency of platelet transfusions in patients who were hospitalized in Suzhou and received multiple(≥2 times) apheresis platelet transfusions from August 2017 to August 2022. Compatibility transfusions were also performed for a subset of acute myeloid leukaemia(AML) patients who completed HLA antibody testing and genotyping. Results From 2017 to 2022,the clinical consumption of platelets in Suzhou has increased annually(P<0.001),and patients who received apheresis platelets were mainly concentrated in hematological diseases represented by hematopoietic or lymphoid tissue tumors,especially AML patients(48.81％,1188/2434). The age group with the highest per capita number of transfusions among AML patients was predominantly 21-30 years old(25 times per person). After genotype-compatible transfusion for eligible AML patients,the CCI significantly increased(P<0.001). Conclusion For male AML patients aged 21-30 and 61-70 in Suzhou,conduc-ting platelet antibody screening and genetic testing before platelet transfusion can improve the efficiency of transfusion,reduce the incidence of PTR,and save blood resources through personalized matching transfusions.
万方数据
维普
